Avazanite Bioscience BV has officially launched its business to commercial stage, to expand patient access to rare disease medicines in Europe while unlocking revenue and growth potential for emerging research-based biopharmaceutical creators.
Avazanite, a fully licensed distributor of medicines, partners with biopharmaceutical collaborators through flexible, tailored licensing and distribution partnerships across Europe. The company’s business model enables global commercialization of promising drugs and addresses unsustainable inequalities in access to innovative orphan drugs across Europe.
Avanzanite was created to fill a market need in the European orphan drug landscape due to the complexity and cost of streamlining business operations in over 30 countries given a limited number of patients and a increasingly difficult market access environment.
The company said most European orphan drug launches – up to 80% – fail to meet their commercial and revenue targets and fail to reach patients in need. The result of this unique market dynamic leaves emerging biopharma companies unmotivated or ill-equipped to establish European operations or enter certain countries.
As a result, an increasing number of biopharmaceutical companies are choosing either not to launch their new orphan drugs in Europe or to exit the market altogether. These dynamics are particularly damaging for emerging biopharmaceutical originators that drive global pharmaceutical innovation, especially for rare diseases. Ultimately, it is patients who pay the price by missing out on promising therapies.
Avanzanite Founder and CEO, Adam Plich, said, “We provide a market-driven solution to the problem of access to orphan drugs in Europe.
“Our inspiration and initial validation of our unique business model stems from our collaboration and an exclusive licensing agreement with SIFI SpA, a leading international ophthalmic company headquartered in Italy. SIFI has partnered with Avanzanite to commercialize and distribute its ultra-orphan investigational drug for the treatment of Acanthamoeba (AK) keratitis – a devastating and highly resistant eye infection that accounts for 50% of blindness in lens wearers. contact – in 26 countries of the European Economic Community. Region and Switzerland.
After more than 15 years of R&D efforts, the European Medicines Agency (EMA) is currently reviewing the product for marketing authorisation.
Widest market access
“While evaluating commercialization options for our orphan drug in several European territories, Avanzanite has convincingly demonstrated why it would be best placed to commercialize and, in fact, provide the widest market access through its unique business model,” said Fabrizio Chines, Chairman and CEO of SIFI.
“Mr. Plich and his team have demonstrated impressive experience in managing the complexity of product launches in the fragmented European market, particularly around pricing and reimbursement, physician engagement and technical operations.
Avanzanite is advancing discussions with several biopharmaceutical companies looking to enter the European market to expand the breadth of their portfolio. Avanzanite said it sees significant opportunities to expand patient access and optimize value creation for originators.
Plich said, “We have cracked the code to decipher this tricky landscape, and now, with our initial strategic partnership with SIFI, we are ready to take our transformation model to the next level by bringing new medicines to patients with diseases rare.
#Avanzanite #Bioscience #seeks #commercialize #innovative #drugs #rare #diseases #Europe